Sandoz’s Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration of Neutropenia

 Shots:

• The approval is based on non-inferiority data with the reference biologic (Neulasta) showing biosimilarity in terms of safety, efficacy and quality
• Ziextenzo is a long-lasting form of filgrastim indicated to reduce duration of neutropenia and occurrence of febrile neutropenia in adult treated with cytotoxic (anti-cancer) CT
• Sandoz has received eight biosimilars approval worldwide, with five in the last 18 months

Click here to read full press release/ article | Ref: Sandoz | Image: Datacenter